TokenPost·
Agenus Reports 72% Pathologic Complete Response in dMMR Colon Cancer Cohort

72%
complete response rate
The 18-patient Phase 2 cohort also met the study’s primary major pathologic response measure in 83% of patients.
Every crypto headline. One feed. Updated every minute.

The 18-patient Phase 2 cohort also met the study’s primary major pathologic response measure in 83% of patients.